61-75 of 931
Gastric Cancer Prevention: A Risk-Based Approach
GI InsightsGastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP
Chul Hyun, MD, PhD, MPH
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Project Oncology®Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD
Apar Kishor Ganti, MD
Thomas Marron, MD, PhD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP
Douglas A. Tremblay, MD
Real-World Outcomes with Axatilimab in cGVHD
Project Oncology®Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP
Hana Safah, MD
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP
Amandeep Salhotra, MD
Current Approaches to Advanced Urothelial Carcinoma
Project Oncology®Current Approaches to Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- advertisement
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Project Oncology®First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Project Oncology®Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Project Oncology®The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
On the Frontlines of Metastatic Breast CancerReal-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
Ryan Quigley
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Project Oncology®Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
- advertisement
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Jason Starr, DO
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS
Prithviraj Bose, MD
Applying Clinical Trial Data in mCSPC Care
Project Oncology®Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD
Jahan Aghalar, MD
Ulka Vaishampayan, MD